List of Pulmonary Studies

Acceleron A011-09 Pulmonary Arterial Hypertension
Lauren Axelrod | (503) 935-8822
Email
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

 

Arena APD811-301 Pulmonary Arterial Hypertension
Lauren Axelrod | (503) 935-8822
Email
A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.

 

AstraZeneca D3250R00023 Severe Asthma
East:
 Donovan Redtomahawk | (503) 963-3093 | Email
West: Lauren Axelrod | (503) 935-8822 | Email
The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States

 

Bellerophon Pulse-PAH-004
Meg Day | (503) 963-3182
Email
A phase 3, placebo controlled, double-blind, randomized, clinical study to determine efficacy, safety and tolerability of pulsed, inhaled Nitric Oxide (iNO) versus placebo in symptomatic subjects with Pulmonary Arterial Hypertension (PAH): INOvation-1.

 

DCRI/Boehringer-Ingelheim 1199.174 IPF
Meg Day | (503) 963-3182
Email
Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry Summary:  This is a multi-center, non-interventional, disease registry of participants with a new diagnosis of IPF.  Participants will be prospectively enrolled in the registry once a diagnosis of IPF is established at the enrolling center.

 

Exact Sciences ES 2016-01 Lung Nodule
Meg Day | (503) 963-3182
Email
Blood Sample Collection in Subjects with Pulmonary Nodules or CT Suspicion of lung cancer (patients 35-79 without planned biopsy/diagnostic procedure OR 50-79 with a planned biopsy or diagnostic procedure).

 

Novartis QAW039 2316 Asthma Study
Donovan Redtomahawk | (503) 963-3093
Email
A 12-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 “Fevipiprant”, an oral prostaglandin DP2 receptor (CRTh2) antagonist (when added to standard-of care asthma therapy in patients with uncontrolled asthma.

 

United Therapeutics RIN-PH-201 Pulmonary Hypertension
Lauren Axelrod | (503) 935-8822
Email
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease

 

United Therapeutics TDE-HF-301 Pulmonary Hypertension
Lauren Axelrod | (503) 935-8822
Email
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects with Pulmonary Hypertension (PH) in Heart Failure with Preserved Ejection Fraction (HFpEF).